Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection-Reference-Cited by-同舟云学术

Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection

Published:2018-07-01 Issue:7 Volume:5 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Dousa Khalid M¹,Babiker Ahmed²,Van Aartsen Daniel¹,Shah Neel²,Bonomo Robert A³⁴⁵,Johnson John L¹,Skalweit Marion J³

Affiliation:

1. Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio

2. Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Ohio

3. Infectious Diseases Section, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio

4. Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio

5. CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio

Abstract

Abstract Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/5/7/ofy168/33591667/ofy168.pdf

Reference17 articles.

1. Increased incidence of cutaneous nontuberculous mycobacterial infection, 1980 to 2009: a population-based study;Wentworth;Mayo Clin Proc,2013

2. Infections from tattooing. Outbreak of Mycobacterium chelonae in France;Goldman;BMJ,2010

3. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin;Wallace;J Infect Dis,1992

4. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases;Griffith;Am J Respir Crit Care Med,2007

5. Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia;Khan;Onco Targets Ther,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disasters pile up on the rubbing heel: Sporothrix globosa as secondary infection to Mycobacterium chelonae infection;Emerging Microbes & Infections;2024-06-10

2. Disseminated nontuberculous mycobacterial infections after allogeneic hematopoietic stem cell transplantation: a risk-based strategy for early diagnosis;Bone Marrow Transplantation;2023-05-20

3. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection;Nature Communications;2022-05-03

4. Infectious complications in patients with chronic lymphocytic leukemia treated with bruton’s tyrosine kinase inhibitors;Medical academic journal;2021-12-06

5. Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria;Frontiers in Immunology;2021-05-25